Arrowhead Research Corp. (ARWR) Forecasted to Earn FY2020 Earnings of $2.16 Per Share
Arrowhead Research Corp. (NASDAQ:ARWR) – Stock analysts at Jefferies Group issued their FY2020 earnings estimates for shares of Arrowhead Research Corp. in a research note issued on Wednesday. Jefferies Group analyst E. Yang anticipates that the brokerage will earn $2.16 per share for the year.
A number of other analysts also recently commented on the company. Cantor Fitzgerald initiated coverage on Arrowhead Research Corp. in a research report on Wednesday, August 17th. They set a “buy” rating and a $15.00 price target for the company. William Blair initiated coverage on Arrowhead Research Corp. in a research report on Friday, August 19th. They set an “outperform” rating for the company. Chardan Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Arrowhead Research Corp. in a research report on Wednesday, September 7th. Finally, Piper Jaffray Cos. decreased their price target on Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating for the company in a research report on Wednesday, August 10th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Arrowhead Research Corp. presently has an average rating of “Buy” and a consensus target price of $10.11.
Arrowhead Research Corp. (NASDAQ:ARWR) traded down 6.52% during mid-day trading on Thursday, hitting $7.03. The stock had a trading volume of 1,547,505 shares. Arrowhead Research Corp. has a 12 month low of $3.07 and a 12 month high of $8.22. The firm’s 50-day moving average is $7.18 and its 200 day moving average is $6.04. The company’s market cap is $427.07 million.
Arrowhead Research Corp. (NASDAQ:ARWR) last released its earnings results on Tuesday, August 9th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. The firm earned $39.58 million during the quarter, compared to the consensus estimate of $0.05 million. Arrowhead Research Corp. had a negative return on equity of 100.50% and a negative net margin of 48,980.81%. The company’s revenue was down 68.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.27) EPS.
Several institutional investors have recently bought and sold shares of the company. State Street Corp raised its position in Arrowhead Research Corp. by 0.3% in the first quarter. State Street Corp now owns 944,860 shares of the company’s stock worth $4,551,000 after buying an additional 3,053 shares during the last quarter. Geode Capital Management LLC raised its position in Arrowhead Research Corp. by 8.3% in the first quarter. Geode Capital Management LLC now owns 408,065 shares of the company’s stock worth $1,966,000 after buying an additional 31,293 shares during the last quarter. Falcon Point Capital LLC raised its position in Arrowhead Research Corp. by 12.5% in the second quarter. Falcon Point Capital LLC now owns 49,147 shares of the company’s stock worth $261,000 after buying an additional 5,458 shares during the last quarter. Bank of New York Mellon Corp raised its position in Arrowhead Research Corp. by 7.1% in the second quarter. Bank of New York Mellon Corp now owns 290,559 shares of the company’s stock worth $1,547,000 after buying an additional 19,376 shares during the last quarter. Finally, California State Teachers Retirement System raised its position in Arrowhead Research Corp. by 0.7% in the second quarter. California State Teachers Retirement System now owns 126,906 shares of the company’s stock worth $675,000 after buying an additional 852 shares during the last quarter. 33.92% of the stock is owned by hedge funds and other institutional investors.
In other Arrowhead Research Corp. news, CFO Kenneth Allen Myszkowski sold 6,900 shares of the firm’s stock in a transaction on Tuesday, August 23rd. The stock was sold at an average price of $8.00, for a total value of $55,200.00. Following the completion of the sale, the chief financial officer now directly owns 128,789 shares of the company’s stock, valued at $1,030,312. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.90% of the stock is owned by company insiders.
About Arrowhead Research Corp.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Receive News & Stock Ratings for Arrowhead Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Research Corp. and related stocks with our FREE daily email newsletter.